The DOI matches its Crossref record.
MA06.03 Efficacy and Safety of Taletrectinib in Patients with ROS1+ Non-Small Cell Lung Cancer: The Global TRUST-II Study
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Approximately one third of patients with ROS1+ NSCLC have brain metastasis at diagnosis, which can be as high as 50% in previously treated patients.
“Approximately one third of patients with ROS1+ NSCLC have a brain metastasis at diagnosis, which can be as high as 50% in previously treated patients.1,30”
From Taletrectinib in ROS1 + Non–Small Cell Lung Cancer: TRUST (2025) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sorted by citations
Taletrectinib in ROS1 + Non–Small Cell Lung Cancer: TRUST
Pérol, M., Li, W., Pennell, N. A., Liu, G., Ohe, Y., De Braud, F., Nagasaka, M., Felip, E., Xiong, A., Zhang, Y., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00275 · Cited by 63
Self-citation
Metadata
- Authors
- Liu, G., Yang, N., Choi, C.-M., Ohe, Y., Sugawara, S., Yanagitani, N., De Braud, F., Nieva, J., Nagasaka, M., Zhou, C., Felip, E., Zhang, X., Lai, R. K., Li, S., Pennell, N. A., Pérol, M., & Bazhenova, L.
- Affiliations
- University of Toronto (CA)
- Central South University (CN)
- Asan Medical Center (KR)
- National Cancer Center Hospital (JP)
- The Cancer Institute Hospital (JP)
- Sendai Kousei Hospital (JP)
- University of Southern California (US)
- University of California, Irvine (US)
- Tongji University (CN)
- Vall d'Hebron Hospital Universitari (ES)
- Cleveland Clinic (US)
- Moores Cancer Center (US)
- ORCID
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2024-10
- Volume
- 19
- Issue
- 10
- Pages
- S72-S73
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W4403420029
- Cited by
- 4
- References
- 0
- Citations by year
- 2025: 3 · 2024: 1
- Type
- conference abstract
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- taletrectinib, ROS1-positive non-small cell lung cancer, ROS1 tyrosine kinase inhibitors, intracranial response, progression-free survival, drug safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
